Clinical And Genetic Epidemiological Study On Efficacy Of Lowering Cholesterol And Toxicity Response To Simvastatin Treatment

Objective 1.To explore the association between baseline fast plasma glucose (FPG) and efficacy of cholesterol lowering in patients with hyperlipemia by Simvastatin treatment.2. To explore whether physical labor in patients with hyperlipemia are assotiated with changes of Creatine Kinase (CK) in serum after Simvastatin treatment.3. The study is conducted to assess the association of ABCC2 polymorphism and changes of CK response to Simvastatin treatment. Methods Patients with serum cholesterol levels TC (5.72~8.32mmol/L) and / or low-density lipoprotein LDL (3.64~6.50mmol/L) were obtained through medical screening in a rural area of Anhui province from March to June in 2005. After informed consent, patients were treated by Simvastatin with the dose of 20mg per day and follow-up for 8 weeks. The effect of lowering TC by Simvastatin and FPG was observed. A total of 408 patients diagnosed with hyperlipemia enrolled the study, which 374 patients completed the study and 34 patients quit. Before patients took Simvastatin, blood lipid, glucose, and other biochemical indicators, and epidemiological questionnaires, physical examination and electrocardiogram monitoring were detected. We extracted DNA and determined genotype by Taqman technology. CK and blood lipid was detected again after the treatment for 4 weeks and 8 weeks. Our data was analysis bye SAS, SPLUS, and other softwares. Results 1. Efficacy of lowering TC: After Simvasatin treatment for 8 weeks, average TC decreased 1. 86mmol/L and decline amounted to 29% in males.Femals decreased 2. 15mmol/L and decline amounted to 32%. 2. Multiple linear regression analysis of FPG and efficacy of lowering TC: From the residual-residual plot of changes and changes percent of lowering TC with Lowess smoothing of SPLUS, that...